Beryl Howard, COPD patient

Helping healthcare professionals to support patients


Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol): Now a carbon neutral triple therapy inhaler, as certified by the Carbon Trust1

A part of delivering GSK’s commitment to have a net zero impact on climate and net positive impact on nature by 2030.

Prescribing information link can be found at the bottom of this webpage.

More resources

Get more from GSKpro

Get access to free patient resources including samples and demo devices, exclusive webinars on the topics that matter to you and updates on the latest in respiratory and more.

Reference

  1. Certification of carbon neutrality for Trelegy Ellipta.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.

November 2021 | PM-GB-NA-WCNT-210003